Merrimack Pharma-Ipsen's Cancer Drug Fails In Overall Survival Measure

Merrimack Pharma-Ipsen's Cancer Drug Fails In Overall Survival Measure
  • Merrimack Pharmaceuticals Inc's MACK partner announced that Ipsen SA IPSEY reported a primary analysis of the results of the Phase 3 trial of Onivyde (irinotecan liposomal injection)for second-line small cell lung cancer (SCLC). 
  • The study did not meet the primary endpoint of overall survival in patients treated with Onivyde versus topotecan. 
  • However, a doubling of the secondary endpoint of objective response rate (ORR) in favor of Onivyde was observed. 
  • The safety and tolerability of Onivyde were consistent with its already-known safety profile, and no new safety concerns emerged. 
  • The clinical study results will be communicated with the regulatory agency." 
  • Ipsen indicated in its update that it would analyze the data further before making decisions about the next steps.
  • "We will continue to monitor updates from Ipsen regarding the SCLC program," said Gary Crocker, Chairman, and CEO of Merrimack Pharmaceuticals. 
  • Ipsen expects to publicly report its top-line data from its continuing Phase 3 study of Onivyde in first-line pancreatic ductal adenocarcinoma before the end of 2022.
  • Price Action: MACK shares are down 13.30% at $4.32 during the market session on the last check Wednesday.

Posted In: Briefswhy it's movingBiotechNewsPenny StocksHealth CareMoversTrading IdeasGeneral